On February 6, 2012, Merck and Co, Inc. in collaboration with the U.S. Food and Drug Administration (FDA) issued a Dear Healthcare Professional letter regarding the potential for lowered drug concentrations when combining certain ritonavir-boosted HIV protease-inhibitors (atazanavir, darunavir, lopinavir) and the hepatitis C protease-inhibitor, boceprevir. Health care providers who are treating patients with this combination are advised to closely monitor patients for HIV viral rebound and hepatitis C treatment response.
Link not available. Boceprevir is no longer marketed in Canada (January 2017)